CURIS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31)
CURIS, INC. (CRIS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) of $1.29 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue · last filed 2013-05-09
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $1.29M, a 81.13% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $764.00K, a 167.13% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $533.00K, a 217.26% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-06-30 was $518.00K.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2012 was $2.52M, a 67.89% increase from fiscal 2011.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2011 was $1.50M, a 32.22% decline from fiscal 2010.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2010 was $2.22M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | $1.29M 10-Q · filed 2013-05-09 | $2.05M derived: sum of 2 quarters · filed 2013-05-09 | $2.58M derived: sum of 3 quarters · filed 2013-05-09 | $3.10M derived: sum of 4 quarters · filed 2013-05-09 |
| 2012-12-31 | $764.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-13 | $1.30M derived: sum of 2 quarters · filed 2013-03-13 | $1.81M derived: sum of 3 quarters · filed 2013-03-13 | $2.52M 10-K · filed 2013-03-13 |
| 2012-09-30 | $533.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $1.05M derived: sum of 2 quarters · filed 2012-11-06 | $1.76M 10-Q · filed 2012-11-06 | $2.05M derived: sum of 4 quarters · filed 2013-05-09 |
| 2012-06-30 | $518.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $1.23M 10-Q · filed 2012-08-09 | $1.51M derived: sum of 3 quarters · filed 2013-05-09 | $1.68M derived: sum of 4 quarters · filed 2013-05-09 |
| 2012-03-31 | $710.00K 10-Q · filed 2013-05-09 | $996.00K derived: sum of 2 quarters · filed 2013-05-09 | $1.16M derived: sum of 3 quarters · filed 2013-05-09 | |
| 2011-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-13 | $454.00K derived: sum of 2 quarters · filed 2013-03-13 | $1.50M 10-K · filed 2013-03-13 | |
| 2011-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $1.22M 10-Q · filed 2012-11-06 | ||
| 2011-06-30 | $1.05M 10-Q · filed 2012-08-09 | |||
| 2010-12-31 | $2.22M 10-K · filed 2013-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |